Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Increase in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 27,250 shares, a growth of 107.6% from the May 31st total of 13,125 shares. Based on an average trading volume of 24,781 shares, the days-to-cover ratio is presently 1.1 days. Currently, 1.6% of the company’s shares are sold short.

Institutional Trading of Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after acquiring an additional 22,200 shares during the last quarter. T3 Companies LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter valued at approximately $208,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Bolt Biotherapeutics in the fourth quarter worth $112,000. Susquehanna International Group LLP acquired a new stake in Bolt Biotherapeutics in the third quarter worth $89,000. Finally, Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics during the third quarter worth $85,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BOLT has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. Finally, Rodman & Renshaw assumed coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $22.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $34.67.

Bolt Biotherapeutics Stock Up 3.6%

Shares of Bolt Biotherapeutics stock opened at $3.99 on Thursday. The business has a fifty day simple moving average of $4.65 and a 200 day simple moving average of $4.98. The stock has a market cap of $7.66 million, a PE ratio of -0.24 and a beta of 1.17. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98. Bolt Biotherapeutics has a 12 month low of $3.75 and a 12 month high of $7.20.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.50 million. Research analysts predict that Bolt Biotherapeutics will post -11.1 EPS for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.